Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quahog, unspecified is an allergenic extract derived from the quahog clam (*Mercenaria mercenaria*). It is utilized as a diagnostic agent in vivo to detect hypersensitivity to quahog shellfish. When administered via skin prick or intradermal injection, the extract's constituent proteins interact with specific IgE antibodies bound to mast cells in sensitized individuals. This interaction triggers the release of histamine and other inflammatory mediators, resulting in a visible wheal-and-flare reaction. Approved by the FDA in 1941 under BLA 103888, it remains a standard tool for clinicians to confirm shellfish allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quahog, unspecified.